Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00135434

Enrollment

Registered

2005-08-26

Start date

2004-09-30

Completion date

2005-06-30

Last updated

2011-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Brief summary

This study examined the effects of two commonly prescribed HIV drugs on the way the body metabolizes glucose, insulin and fat.

Interventions

DRUGAtazanavir/Ritonavir/Lopinavir/ritonavir

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteers

Design outcomes

Primary

Measure	Time frame
Insulin sensitivity by euglycemic hyperinsulinemic clamp method	—

Secondary

Measure	Time frame
Insulin sensitivity by oral glucose tolerance	—
Lipids and lipoproteins	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026